Key facts
- This page summarizes Ph.D. Jonathan B. Rothbard's Form 4 filing for 180 Life Sciences Corp. (ATNF).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Sep 2023, 16:00.
Ph.D. Jonathan B. Rothbard - 04 Sep 2023 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- ATNF
- Reported as of
- 04 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Sep 2023, 16:00:34 UTC
- Prior SEC filing
- 10 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan B. Rothbard, Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Jonathan B. Rothbard filed Form 4 for 180 Life Sciences Corp. (ATNF) on 08 Sep 2023.
Change
- Previous filing in this sequence was filed on 10 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATNF
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 28,023
- Date
- 04 Sep 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATNF
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 04 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $0.6700
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Stock Options were granted to the Reporting Person pursuant to the Issuer's First Amended and Restated 2022 Omnibus Incentive Plan in consideration for services to be rendered as Chief Scientific Officer. Exempt from Section 16(b) pursuant to Rule 16b-3.
Footnote F2
The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.